Fezolinetant: First Approval

Fezolinetant (VEOZAH™) is an oral, small molecule, neurokinin 3 receptor (NK3R) antagonist, which is being developed by Astellas Pharma Inc. for the treatment of moderate to severe vasomotor symptoms (VMS) or hot flashes due to menopause. Inhibiting NK3R-mediated signalling in the central nervous sy...

Full description

Saved in:
Bibliographic Details
Published in:Drugs (New York, N.Y.) N.Y.), 2023-08, Vol.83 (12), p.1137-1141
Main Author: Lee, Arnold
Format: Article
Language:English
Subjects:
AdisInsight Report
Central nervous system
Contraindications
Drug dosages
Hot flash
Internal Medicine
Liver cirrhosis
Medicine
Medicine & Public Health
Menopause
Neurokinin
Neurokinin NK3 receptors
Pharmaceuticals
Pharmacology/Toxicology
Pharmacotherapy
Plasma
Thermoregulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fezolinetant (VEOZAH™) is an oral, small molecule, neurokinin 3 receptor (NK3R) antagonist, which is being developed by Astellas Pharma Inc. for the treatment of moderate to severe vasomotor symptoms (VMS) or hot flashes due to menopause. Inhibiting NK3R-mediated signalling in the central nervous system is a non-hormonal strategy to modulate the activity of neurones that are associated with thermoregulation, thereby reducing the frequency and severity of VMS. Fezolinetant received its first approval in the USA in May 2023 for the treatment of moderate to severe VMS due to menopause. This article summarizes the milestones in the development of fezolinetant leading to this first approval in this indication.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-023-01917-1